Helena Eriksson

803 total citations
23 papers, 618 citations indexed

About

Helena Eriksson is a scholar working on Immunology, Molecular Biology and Oncology. According to data from OpenAlex, Helena Eriksson has authored 23 papers receiving a total of 618 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Immunology, 8 papers in Molecular Biology and 7 papers in Oncology. Recurrent topics in Helena Eriksson's work include S100 Proteins and Annexins (6 papers), Immune Response and Inflammation (5 papers) and Immune cells in cancer (4 papers). Helena Eriksson is often cited by papers focused on S100 Proteins and Annexins (6 papers), Immune Response and Inflammation (5 papers) and Immune cells in cancer (4 papers). Helena Eriksson collaborates with scholars based in Sweden, Germany and Netherlands. Helena Eriksson's co-authors include Lars Eklundh, Tiit Nilson, Andres Kuusk, Karin Hall, Anders Lindroth, Tomas Leanderson, Marie Törngren, Jonas Ardö, Petter Pilesjö and Helén Tuvesson and has published in prestigious journals such as Blood, PLoS ONE and Remote Sensing of Environment.

In The Last Decade

Helena Eriksson

23 papers receiving 589 citations

Peers

Countries citing papers authored by Helena Eriksson

Since Specialization

Citations

This map shows the geographic impact of Helena Eriksson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helena Eriksson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helena Eriksson more than expected).

Fields of papers citing papers by Helena Eriksson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helena Eriksson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helena Eriksson. The network helps show where Helena Eriksson may publish in the future.

Co-authorship network of co-authors of Helena Eriksson

This figure shows the co-authorship network connecting the top 25 collaborators of Helena Eriksson. A scholar is included among the top collaborators of Helena Eriksson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helena Eriksson. Helena Eriksson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	S100A8/S100A9 Promote Progression of Multiple Myeloma via Expansion of Megakaryocytes 2023 ·Cancer Research Communications ·Cindy Lin, Laura Garcia-Gerique, (unknown), Jérôme Mastio, (unknown), (unknown), (unknown), (unknown), Kar Muthumani, Qin Liu, Mortimer Poncz, Thomas Vogl, Marie Törngren, Helena Eriksson, Dan T. Vogl, Dmitry I. Gabrilovich, Yulia Nefedova	9
2	Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma 2023 ·Journal for ImmunoTherapy of Cancer ·Rong Fan, (unknown), (unknown), (unknown), Philip Vlummens, Anke Maes, (unknown), Elke De Bruyne, Eline Menu, Holly Evans, Andrew Chantry, Nathan De Beule, Dirk Hose, Marie Törngren, Helena Eriksson, Karin Vanderkerken, Ken Maes, Karine Breckpot, Kim De Veirman	12
3	Targeting S100A9 protein affects mTOR-ER stress signaling and increases venetoclax sensitivity in Acute Myeloid Leukemia 2023 ·Blood Cancer Journal ·Rong Fan, (unknown), (unknown), (unknown), Elke De Bruyne, Eline Menu, Nathan De Beule, Ann De Becker, Gamze Ates, Ann Massie, Tessa Kerre, Marie Törngren, Helena Eriksson, Karin Vanderkerken, Karine Breckpot, Ken Maes, Kim De Veirman	4
4	An open-label study to evaluate biomarkers and safety in systemic sclerosis patients treated with paquinimod 2021 ·Arthritis Research & Therapy ·Roger Hesselstrand, Jörg H. W. Distler, Gabriela Riemekasten, Dirk M. Wuttge, Marie Törngren, (unknown), Fredrik Andersson, Helena Eriksson, Birgitta Sparre, Helén Tuvesson, Oliver Distler	32
5	Tasquinimod Targets Immunosuppressive Myeloid Cells, Increases Osteogenesis and Has Direct Anti-Myeloma Effects By Inhibiting c-Myc Expression in Vitro and In Vivo 2021 ·Blood ·Rong Fan, (unknown), (unknown), Elke De Bruyne, Eline Menu, Andrew Chantry, Holly Evans, Marie Törngren, Helena Eriksson, Karine Breckpot, Ken Maes, Karin Vanderkerken, Kim De Veirman	1
6	Assessment of requests for medication-related follow-up after hospital discharge, and the relation to unplanned hospital revisits, in older patients: a multicentre retrospective chart review 2021 ·BMC Geriatrics ·(unknown), Thomas Kempen, Helena Eriksson, (unknown), (unknown), Ulrika Gillespie	3
7	Targeting the Inflammatory Niche in MDS By Tasquinimod Restores Hematopoietic Support and Suppresses Immune-Checkpoint Expression in Vitro 2021 ·Blood ·Manja Wobus, Ekaterina Balaian, Uta Oelschlaegel, Russell Towers, (unknown), (unknown), Rebekka Wehner, Friedrich Stölzel, Triantafyllos Chavakis, Marie Törngren, Helena Eriksson, Uwe Platzbecker, Christoph Röllig, Martin Bornhäuser, Katja Sockel	2
8	A Phase 1 Study of Tasquinimod in Patients with Relapsed or Refractory Multiple Myeloma 2020 ·Blood ·Dan T. Vogl, Yulia Nefedova, E. Paul Wileyto, (unknown), (unknown), Nguyễn Văn Vĩnh Châu, (unknown), Eva Bondesson, Helena Eriksson, Helén Tuvesson	4
9	Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion 2017 ·Cancer Immunology Research ·Kim De Veirman, Nathan De Beule, Ken Maes, Eline Menu, Elke De Bruyne, Hendrik De Raeve, Karel Fostier, Jérôme Moreaux, Alboukadel Kassambara, Dirk Hose, Roy Heusschen, Helena Eriksson, Karin Vanderkerken, Els Van Valckenborgh	44
10	Paquinimod reduces skin fibrosis in tight skin 1 mice, an experimental model of systemic sclerosis 2016 ·Journal of Dermatological Science ·Martin Stenström, (unknown), Marie Törngren, David Liberg, Birgitta Sparre, Helén Tuvesson, Helena Eriksson, Tomas Leanderson	41
11	Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis 2015 ·Annals of the Rheumatic Diseases ·R. Schelbergen, E.J. Geven, Martijn H. J. van den Bosch, Helena Eriksson, Tomas Leanderson, Thomas Vogl, Johannes Roth, Fons A. J. van de Loo, Marije I. Koenders, P.M. van der Kraan, Wim B. van den Berg, Arjen B. Blom, Peter L. E. M. van Lent	71
12	Tasquinimod Modulates Suppressive Myeloid Cells and Enhances Cancer Immunotherapies in Murine Models 2014 ·Cancer Immunology Research ·Li Shen, Anette Sundstedt, Michael J. Ciesielski, Kiersten Marie Miles, (unknown), Remi Adelaiye‐Ogala, Ashley Orillion, Eric Ciamporcero, Swathi Ramakrishnan, Leigh Ellis, Robert A. Fenstermaker, Scott I. Abrams, Helena Eriksson, Tomas Leanderson, Anders Olsson, Роберто Пили	74
13	The S100A9 inhibitor paquinimod (ABR-215757) reduces synovial activation, osteophyte formation and cartilage damage in experimental osteoarthritis 2014 ·Osteoarthritis and Cartilage ·R. Schelbergen, (unknown), Tomas Leanderson, Helena Eriksson, Wim B. van den Berg, P.M. van der Kraan, P.L. van Lent	1
14	FRI0516 Paquinimod (ABR-215757), an Immunomodulatory Compound, Reduces Fibrosis in the Tight Skin-1 (TSK-1) Model for Systemic Sclerosis 2014 ·Annals of the Rheumatic Diseases ·Martin Stenström, (unknown), Mats Nilsson, Helena Eriksson, Marie Törngren, J. Distler, Oliver Distler, Birgitta Sparre, Helén Tuvesson	1
15	FRI0496 An Open-Label Study to Evaluate Biomarkers and Safety in Systemic Sclerosis (SSC) Patients Treated with Paquinimod (ABR-215757) 2014 ·Annals of the Rheumatic Diseases ·Roger Hesselstrand, Jörg H. W. Distler, Gabriela Riemekasten, Marie Törngren, (unknown), Martin Stenström, Fredrik Andersson, Helena Eriksson, Birgitta Sparre, Helén Tuvesson, Oliver Distler	3
16	The Tumor Targeted Superantigen ABR-217620 Selectively Engages TRBV7-9 and Exploits TCR-pMHC Affinity Mimicry in Mediating T Cell Cytotoxicity 2013 ·PLoS ONE ·Gunnar Hedlund, Helena Eriksson, Anette Sundstedt, G. Forsberg, Bent K. Jakobsen, Nicholas J. Pumphrey, Karin E. J. Rödström, Karin Lindkvist‐Petersson, Per Björk	14
17	Abstract B17: Immunomodulation by tasquinimod: Combination with immunotherapy results in enhanced CD8 T cell responses and improved antitumor effects. 2013 ·Cancer Research ·Anette Sundstedt, Anders Olsson, Martin Stenström, (unknown), Marie Törngren, Helena Eriksson, Gunnar Hedlund, David Liberg, Tomas Leanderson	1
18	Monotherapeutically Nonactive CTLA-4 Blockade Results in Greatly Enhanced Antitumor Effects When Combined With Tumor-targeted Superantigens in a B16 Melanoma Model 2012 ·Journal of Immunotherapy ·Anette Sundstedt, (unknown), Helena Eriksson, Marie Törngren, Gunnar Hedlund	8
19	Impact of understory vegetation on forest canopy reflectance and remotely sensed LAI estimates 2006 ·Remote Sensing of Environment ·Helena Eriksson, Lars Eklundh, Andres Kuusk, Tiit Nilson	156
20	DNA-binding dependent and independent functions of WT1 protein during human hematopoiesis 2005 ·Experimental Cell Research ·(unknown), Helena Eriksson, Christos Gekas, Tor Olofsson, Johan Richter, Urban Gullberg	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact